Groupe Francais De Pneumo-cancerologie
Clinical trials sponsored by Groupe Francais De Pneumo-cancerologie, explained in plain language.
-
New hope for lung cancer: targeted drug plus local therapy may delay progression
Disease control Recruiting nowThis study is for people with advanced non-small cell lung cancer that has a specific genetic change (ALK rearrangement). Participants take the targeted drug brigatinib, and if their disease shrinks or stabilizes with few remaining tumors, they also receive local treatments like …
Phase: PHASE2 • Sponsor: Groupe Francais De Pneumo-Cancerologie • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Scientists probe resistance to targeted lung cancer drug
Knowledge-focused Recruiting nowThis study looks at why amivantamab, a drug for advanced non-small cell lung cancer with a specific EGFR mutation, stops working over time. Researchers will collect blood and tumor samples from 30 patients when their disease gets worse. The goal is to find genetic changes that ca…
Phase: NA • Sponsor: Groupe Francais De Pneumo-Cancerologie • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:09 UTC
-
Scientists dig deeper into ALK lung cancer to unlock resistance secrets
Knowledge-focused Recruiting nowThis study looks at the biological features of a specific type of lung cancer (ALK-positive) in 100 patients. Researchers will analyze tumor samples and blood tests taken at diagnosis and when the disease worsens. The goal is to learn why some treatments stop working, not to test…
Phase: NA • Sponsor: Groupe Francais De Pneumo-Cancerologie • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:02 UTC